Keywords: Dendreon, Provenge, USA, Medicare, CMS

Dendreon shares plunge as Medicare considers coverage of prostate cancer drug Provenge

Article | 02 July 2010

Print This

The USA’s federal Centers for Medicare and Medicaid Services (CMS) health program has said it is evaluating the recently-approved ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in